[The assessment of TIKLO efficacy in patients with intermittent claudication].

Abstract

The efficacy of TIKLO was compared with acetylsalicylic acid in treatment of patients with intermittent claudication. Patients were divided into 2 groups (30 and 33 subjects). The first group received TIKLO (250 mg, BID), the second one - Thrombo ASS (100 mg, QD). Outcome measures included platelet aggregation, walking distance and the time of ankle-brachial index (ABI) recovery after treadmill test. TIKLO was shown to reduce platelet aggregation, increase pain-free walking distance and decrease the time of ABI recovery after treadmill test. TIKLO administration was accompanied with minimal adverse events.

• Authors: I I Zatevakhin, V N Zolkin, E E Shiller
• Journal: Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery (Angiol Sosud Khir) Vol. 13 Issue 2 Pg. 19-23 ( 2007) ISSN: 1027-6661 [Print] Russia (Federation)
• PMID: 18004255 (Publication Type: Case Reports, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Platelet Aggregation Inhibitors
• Ticlopidine

Topics

• Aged
• Atherosclerosis (drug therapy, epidemiology, physiopathology)
• Exercise Test
• Female
• Humans
• Intermittent Claudication (diagnosis, drug therapy, epidemiology)
• Lower Extremity (blood supply, physiopathology)
• Male
• Movement Disorders (epidemiology, etiology)
• Myocardial Ischemia (drug therapy, epidemiology)
• Platelet Aggregation Inhibitors (therapeutic use)
• Severity of Illness Index
• Ticlopidine (therapeutic use)
• Treatment Outcome